Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Oncology Market Estimated to Expand 26% by 2030: Fuji Keizai
November 22, 2022
- Nucala Pediatric Form, Berinert SC, Upgraded Diquas Now Available
November 22, 2022
- Kyowa Kirin/MEI Deliver in Japan PII Trial for B-Cell Non-Hodgkin’s Lymphoma
November 21, 2022
- Alnylam’s Amvuttra Hits Japan Market for hATTR Amyloidosis
November 21, 2022
- Astellas’s Zolbetuximab Hits Goals in PIII Gastric Cancer Trial
November 18, 2022
- RaQualia Gets US$4 Million from Asahi Kasei for Chronic Pain Drug Milestone
November 18, 2022
- Horizon Completes Enrollment of Japan PIII for Thyroid Eye Disease Drug
November 18, 2022
- Yoshindo Bags Japan Sales Rights for Stelara, Pralia Biosimilars from India’s Biocon
November 18, 2022
- Big 3 Generic Firms Struggle in H1; Nichi-Iko Logs Excess Debt as Profits Tank for Rivals
November 18, 2022
- Nichi-Iko Asks for Debt Waiver from Creditors in Turnaround Plan
November 17, 2022
- Sotyktu, Spevigo, Fintepla, Koselugo, and More Now Available in Japan
November 17, 2022
- Merck R&D Chief Confident on Expanding Pipeline towards Keytruda Patent Cliff and Beyond
November 17, 2022
- Top 4 Wholesalers on Recovery Trend, Operating Profit Up 69.1% in April-September
November 16, 2022
- Daiichi Sankyo’s COVID Jab Hits Mark in Japan Booster Trial, Filing Set for January
November 16, 2022
- Takeda’s CMV Drug Livtencity Approved in Europe
November 16, 2022
- Ono Hooks Up with Polish Upstart on Neuroscience Drug Discovery
November 15, 2022
- Nichi-Iko to Be Delisted, Seeks Turnaround under Medipal-JWP Joint Firm; President to Bow Out
November 15, 2022
- Nichi-Iko Logs 35.6 Billion Yen in Excess Debt in April-September
November 15, 2022
- Enhertu Gets EU Panel Backing for Second-Line Gastric Cancer
November 15, 2022
- Asian Regulatory Harmonization Underutilized by Japan Drug Makers, Priorities on Western Markets
November 14, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…